Patents Assigned to INVECTYS SAS
  • SINGLE-DOMAIN ANTIBODIES DIRECTED AGAINST LILRB2
    Publication number: 20230235050
    Abstract: The present invention relates to single-domain antibodies (sdAbs) directed against Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2), pharmaceutical compositions comprising
    Type: Application
    Filed: September 18, 2020
    Publication date: July 27, 2023
    Applicant: Invectys SAS
    Inventors: Maria LOUSTAU, Lise HUNAULT, Pierre LANGLADE DEMOYEN, Julien CAUMARTIN
  • Recombinant measles vaccine expressing hTERT
    Patent number: 11351246
    Abstract: The invention relates a recombinant measles virus plasmid capable of expressing a human telomerase reverse transcriptase (hTERT) protein fused at N-terminus with a protein enhancing addressing of the hTERT protein to proteasome. The invention further relates to a vaccine comprising said plasmid or particles rescued therefrom, and uses thereof, especially in preventing or treating a tumor in a patient.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: June 7, 2022
    Assignees: INVECTYS SAS, INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Pierre Langlade Demoyen, Frédéric Tangy, Elodie Pliquet